Free Trial
→ The Man I Turn to In Times Like This (From Stansberry Research) (Ad)
OTCMKTS:ZLDPF

Zealand Pharma A/S 5/11/2023 Earnings Report

Zealand Pharma A/S logo
$75.15 +4.82 (+6.85%)
As of 05/2/2025 09:30 AM Eastern
Earnings HistoryForecast

Zealand Pharma A/S EPS Results

Actual EPS
-$0.54
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$1.96 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Date
5/11/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zealand Pharma A/S' next earnings date is estimated for Wednesday, May 7, 2025, based on past reporting schedules.

Conference Call Resources

Zealand Pharma A/S Earnings Headlines

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
May 2 at 1:19 AM | cnbc.com
Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes
April 24, 2025 | reuters.com
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
May 3, 2025 | Timothy Sykes (Ad)
Zealand Pharma appoints Utpal Singh as CSO
April 23, 2025 | markets.businessinsider.com
Zealand Pharma Hires Lilly Executive as Biotech Ramps Up in Obesity
April 23, 2025 | msn.com
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025
April 19, 2025 | finance.yahoo.com
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

View Zealand Pharma A/S Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles